Member Directory
Profile
Nicolas Villain, M.D., Ph.D.
Institute of Memory and Alzheimer's Disease
Contact Information
Nicolas Villain, M.D., Ph.D.
Paris, France
Professional Information
Dr.
Institute of Memory and Alzheimer's Disease
https://twitter.com/nvillain_alz
Education
- Fellowship in Behavioral & Cognitive Neurology, Department of Neurology, Pitié-Salpêtrière Hospital, Paris, France: 2017-2021 - Board Certification in Neurology, 2017 - MD, 2017 - Resident in Neurology, Assistance Publique – Hôpitaux de Paris (AP-HP) : 2012-2017 - PhD in Neuroscience, 2009 - MSc Cellular Biology and Neuroscience, 2006 - Inserm-Liliane Bettencourt MD-PhD Program, 2004 - Medical School, University of Caen Normandy: 2002-2005 & 2009-2012Financial Disclosure
Member reports the following financial or other potential conflicts of interest:
[Last updated: Oct 11, 2022]
NV received research support from Fondation Bettencourt-Schueller, Fondation Servier, Union Nationale pour les Intérêts de la Médecine (UNIM), Fondation Claude Pompidou, Fondation Alzheimer and Fondation pour la Recherche sur l’Alzheimer; travel grant from the Movement Disorders Society, Merz-Pharma, UCB Pharma, and GE Healthcare SAS; is an unpaid principal investigator or sub-investigator in NCT04241068 (aducanumab, Biogen), NCT04437511 (donanemab, Eli-Lilly), NCT05463731 (remternetug, Eli-Lilly), NCT04592341 (gantenerumab, Roche), NCT03887455 (lecanemab, Eisai), NCT03352557 (gosuranemab, Biogen), NCT03828747 and NCT03289143 (semorinemab, Roche), NCT04619420 (JNJ-63733657, Janssen – Johnson & Johnson), NCT04374136 (AL001, Alector), NCT04592874 (AL002, Alector), NCT04867616 (bepranemab, UCB Pharma), NCT04777396 and NCT04777409 (semaglutide, Novo Nordisk); and has given unpaid lectures in symposia organized by Eisai and the Servier Foundation.